GlassScriptPhysician profile
Sara R Buchstein
NPI 1134101314
$9,245.58
in general payments reported to CMS, 2019-2025
19 companies · $791 in 2025
The $791 reported for 2025 was more than what 75% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $1,612 · 2021: $2,612 · 2022: $2,120 · 2023: $916 · 2024: $700 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,407.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,997.21 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Cipla USA INC. | $1,973.26 | 2021-2022 | |
| Gilead Sciences, INC. | $1,008.03 | 2019-2025 | Biktarvy |
| Janssen Biotech, INC. | $775.99 | 2019-2023 | Symtuza |
| Insmed, INC. | $692.93 | 2019-2025 | Arikayce |
| Abbvie INC. | $576.97 | 2020-2025 | Avycaz, Mavyret, Teflaro |
| Melinta Therapeutics, LLC | $539.47 | 2019-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Merck Sharp & Dohme LLC | $526.87 | 2020-2025 | Dificid, Zerbaxa, Pifeltro |
| Paratek Pharmaceuticals, INC. | $327.03 | 2020-2024 | Nuzyra |
| Janssen Products, LP | $178.99 | 2021-2022 | |
| Cumberland Pharmaceuticals, INC. | $168.59 | 2019-2025 | Vibativ |
| Vyera Pharmaceuticals, LLC | $167.76 | 2019-2021 | |
| Allergan, INC. | $112.18 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $61.75 | 2019-2020 | |
| Astellas Pharma US INC | $55.90 | 2019-2023 | Cresemba |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $24.21 | 2020-2021 | |
| Shionogi INC | $22.48 | 2023 | Fetroja |
| Redhill Biopharma INC. | $19.34 | 2020 | |
| Shire North American Group INC | $16.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Buchstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.